Figure 3.

Inhibition of complement and coagulation pathways by Iripin-8. (A) Iripin-8 inhibits the intrinsic coagulation pathway. Human plasma was preincubated with increasing concentrations of Iripin-8 (94 nM–6 μM). Coagulation was triggered by the addition of Dapttin^® reagent and CaCl₂, and clot formation time was measured. A sample without Iripin-8 was used as a control for statistical purposes. (B) Iripin-8 delays fibrin clot formation in a thrombin time assay in a dose-dependent manner. Coagulation of human plasma was initiated by thrombin reagent preincubated with various concentrations of Iripin-8, and thrombin time was measured. Samples without Iripin-8 were used as a control for statistical purposes. (C) Iripin-8 inhibits erythrocyte lysis by human complement. Human plasma was preincubated with increasing concentrations of Iripin-3, 5, and 8 (312 nM–10 μM). After the addition of rabbit erythrocytes, their lysis time by complement was measured. Values represent prolongation of time needed for erythrocyte lysis compared with the control group. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.